全球痴呆症与阿兹海默症相关市场研究报告 - 2024 年至 2032 年行业分析、规模、份额、成长、趋势和预测

预计到 2032 年，全球阿兹海默症相关失智症的市场规模将从 2023 年的 76 亿美元达到近 119.3 亿美元，2024 年至 2032 年研究期间的CAGR为 5.14%。

与阿兹海默症相关的痴呆症属于一种独特形式的认知障碍，主要是由与阿兹海默症特征一致的大脑变化引起的。阿兹海默症是痴呆症的主要原因，涵盖了与这种认知障碍相关的绝大多数病例。

市场动态

与阿兹海默症相关的痴呆症周围的情况受到几个关键因素的影响。全球人口老化是主要驱动因素，因为年龄是阿兹海默症的重要危险因子。人口结构的变化导致面临风险的人数不断增加，从而促进了研究工作的加强、诊断技术的进步和药物的开发。正在进行的研究和临床试验旨在了解阿兹海默症的根本原因，识别生物标记并开发有效的治疗方法。政府和非营利组织为研究、宣传活动和支援服务提供资金。药品市场受到发现可以改变疾病进程或控制其症状的药物的努力的影响。此外，对护理人员支援服务的需求正在上升，反映出受阿兹海默症影响的人数不断增加。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球阿兹海默症相关痴呆市场的各个细分市场进行了包容性评估。与阿兹海默症行业相关的痴呆症的增长和趋势为本研究提供了整体方法。

市场区隔

与阿兹海默症相关的痴呆症市场报告的这一部分提供了国家和区域层面的详细资料，从而帮助策略家确定相应产品或服务的目标人口统计数据以及即将到来的机会。

按药物类别

• 胆碱能/胆碱酯酶 (Che) 抑制剂
• 美金刚
• 联合药物（美金刚和多奈哌齐）
• 其他的

按配销通路

• 医院药房
• 零售
• 网上销售

区域分析

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲的阿兹海默症相关痴呆症市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。与阿兹海默症相关的失智症市场的主要参与者包括 Merz Pharma、诺华公司、艾伯维公司、辉瑞公司、第一三共有限公司、小野製药有限公司、强生服务公司、卫材有限公司(Eisai Co., Ltd.)、H. Lundbeck A/S、F. Hoffmann-La Roche Ltd. 本部分包含竞争格局的整体视图，其中包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概览、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：与阿兹海默症相关的痴呆症 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按药品类别分類的市场吸引力分析
  • 按配销通路分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球与阿兹海默症相关的痴呆症市场分析：按药物类别

• 按药物类别概述
• 历史和预测数据
• 按药物类别分析
• 胆碱能/胆碱酯酶 (ChE) 抑制剂
• 美金刚
• 联合药物（美金刚和多奈哌齐）
• 其他的

第 6 章：全球与阿兹海默症相关的痴呆症市场分析：按分销管道

• 按配销通路分類的概览
• 历史和预测数据
• 按配销通路分析
• 医院药房
• 零售
• 网上销售

第 7 章：全球与阿兹海默症相关的痴呆症市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 8 章：阿兹海默症相关痴呆症公司的竞争格局

• 痴呆症与阿兹海默症市场竞争有关
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 9 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• Merz Pharma
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Novartis AG
• 公司简介
• 公司收入
• 产品
• 最近的发展
• AbbVie Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Daiichi Sankyo Company Limited.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Ono Pharmaceutical Co. Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Johnson & Johnson Services Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Eisai Co. Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• H. Lundbeck A/S
• 公司简介
• 公司收入
• 产品
• 最近的发展
• F. Hoffmann-La Roche Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Dementia Associated with Alzheimer's Disease Market is presumed to reach the market size of nearly USD 11.93 Billion by 2032 from USD 7.6 Billion in 2023 with a CAGR of 5.14% under the study period 2024 - 2032.

Dementia linked to Alzheimer's disease pertains to a distinct form of cognitive impairment primarily instigated by alterations in the brain consistent with the characteristics of Alzheimer's disease. Alzheimer's disease constitutes the predominant cause of dementia, encompassing a substantial majority of cases associated with this cognitive disorder.

MARKET DYNAMICS

The landscape surrounding dementia associated with Alzheimer's disease is influenced by several key factors. The increasing aging population globally is a primary driver, as age is a significant risk factor for Alzheimer's disease. The shift in demographics has resulted in a rising number of individuals at risk, prompting heightened research efforts, advancements in diagnostics, and developments in pharmaceuticals. Ongoing research and clinical trials seek to understand the underlying causes of Alzheimer's, identify biomarkers, and develop effective treatments. Government and nonprofit initiatives contribute to funding for research, awareness campaigns, and support services. The pharmaceutical market is influenced by efforts to discover drugs that can modify the course of the disease or manage its symptoms. Additionally, the demand for caregiver support services is rising, reflecting the increasing number of individuals affected by Alzheimer's disease.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of dementia associated with alzheimer's disease. The growth and trends of dementia associated with alzheimer's disease industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the dementia associated with alzheimer's disease market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Drug Class

• Cholinergic/Cholinesterase (Che) Inhibitors
• Memantine
• Combined Drugs (Memantine & Donepezil)
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail
• Online Sales

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Dementia Associated with Alzheimer's Disease market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Dementia Associated with Alzheimer's Disease market include Merz Pharma, Novartis AG, AbbVie Inc., Pfizer, Inc., Daiichi Sankyo Company, Limited., Ono Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Eisai Co., Ltd., H. Lundbeck A/S, F. Hoffmann-La Roche Ltd. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Drug Class
  • 3.7.2 Market Attractiveness Analysis By Distribution Channel
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE MARKET ANALYSIS BY DRUG CLASS

• 5.1 Overview by Drug Class
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Drug Class
• 5.4 Cholinergic/Cholinesterase (ChE) Inhibitors Historic and Forecast Sales by Regions
• 5.5 Memantine Historic and Forecast Sales by Regions
• 5.6 Combined Drugs (Memantine & Donepezil) Historic and Forecast Sales by Regions
• 5.7 Others Historic and Forecast Sales by Regions

6 . GLOBAL DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 6.1 Overview by Distribution Channel
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Distribution Channel
• 6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
• 6.5 Retail Historic and Forecast Sales by Regions
• 6.6 Online Sales Historic and Forecast Sales by Regions

7 . GLOBAL DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE COMPANIES

• 8.1. Dementia Associated With Alzheimer'S Disease Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF DEMENTIA ASSOCIATED WITH ALZHEIMER'S DISEASE INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. Merz Pharma
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. Novartis AG
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. AbbVie Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. Pfizer Inc.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. Daiichi Sankyo Company Limited.
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Ono Pharmaceutical Co. Ltd.
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Johnson & Johnson Services Inc.
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Eisai Co. Ltd.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments
• 9.11. H. Lundbeck A/S
  • 9.11.1. Company Overview
  • 9.11.2. Company Revenue
  • 9.11.3. Products
  • 9.11.4. Recent Developments
• 9.12. F. Hoffmann-La Roche Ltd.
  • 9.12.1. Company Overview
  • 9.12.2. Company Revenue
  • 9.12.3. Products
  • 9.12.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Drug Class (USD MN)
• Cholinergic/Cholinesterase (ChE) Inhibitors Market Sales by Geography (USD MN)
• Memantine Market Sales by Geography (USD MN)
• Combined Drugs (Memantine & Donepezil) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Market Sales by Geography (USD MN)
• Online Sales Market Sales by Geography (USD MN)
• Global Dementia Associated With Alzheimer'S Disease Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Dementia Associated With Alzheimer'S Disease Report
• Market Research Process
• Market Research Methodology
• Global Dementia Associated With Alzheimer'S Disease Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Drug Class
• Market Attractiveness Analysis by Distribution Channel
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Drug Class (USD MN)
• Cholinergic/Cholinesterase (ChE) Inhibitors Market Sales by Geography (USD MN)
• Memantine Market Sales by Geography (USD MN)
• Combined Drugs (Memantine & Donepezil) Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Distribution Channel (USD MN)
• Hospital Pharmacies Market Sales by Geography (USD MN)
• Retail Market Sales by Geography (USD MN)
• Online Sales Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.